Overview
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
Indication
用于已转移的前列腺癌,可与手术或化学去势合用。
Associated Conditions
- Metastatic Prostate Cancer
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2018/09/19 | Phase 3 | Recruiting | |||
2017/03/06 | Phase 2 | Active, not recruiting | |||
2013/02/07 | Phase 2 | Active, not recruiting | |||
2009/06/11 | Phase 2 | Terminated | |||
2007/08/08 | Phase 1 | Terminated | |||
2003/01/27 | Phase 3 | Completed | |||
2003/01/27 | Phase 2 | Completed | |||
2003/01/27 | Phase 2 | Completed | |||
2003/01/27 | Phase 3 | Completed | |||
2003/01/27 | Phase 3 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
Prasco Laboratories | 66993-212 | ORAL | 150 mg in 1 1 | 11/22/2019 | |
ANI Pharmaceuticals, Inc. | 62559-173 | ORAL | 150 mg in 1 1 | 9/18/2020 | |
Concordia Pharmaceuticals Inc. | 59212-111 | ORAL | 150 mg in 1 1 | 7/8/2022 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
---|---|---|---|---|---|
ANANDRON TAB 50MG | roussel canada inc. | 00863890 | Tablet - Oral | 50 MG / TAB | 12/31/1992 |
ANANDRON - TAB 100MG | aventis pharma inc | 02221888 | Tablet - Oral | 100 MG | 8/20/1997 |
ANANDRON TAB 50MG | hoechst roussel canada inc. | 01989642 | Tablet - Oral | 50 MG / TAB | 12/31/1994 |
ANANDRON TAB 100MG | roussel canada inc. | 00863904 | Tablet - Oral | 100 MG / TAB | 12/31/1992 |
ANANDRON TAB 100MG | hoechst roussel canada inc. | 01989650 | Tablet - Oral | 100 MG / TAB | 12/31/1992 |
ANANDRON | 02221861 | Tablet - Oral | 50 MG | 8/20/1997 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
---|---|---|---|---|---|
No CIMA AEMPS (Spain) approvals found for this drug. |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Philippines FDA approvals found for this drug. |
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Saudi SFDA approvals found for this drug. |
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Malaysia NPRA approvals found for this drug. |
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
---|---|---|---|---|---|
No UK EMC drug information found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.